Senti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan Capital

Senti Biosciences (NASDAQ:SNTI)‘s stock had its “buy” rating reissued by research analysts at Chardan Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. Chardan Capital’s price target would indicate a potential downside of 20.51% from the company’s previous close.

Senti Biosciences Price Performance

Shares of NASDAQ SNTI traded up $10.42 during midday trading on Monday, hitting $12.58. 88,910,875 shares of the company’s stock were exchanged, compared to its average volume of 573,981. Senti Biosciences has a twelve month low of $1.52 and a twelve month high of $16.94. The firm has a market cap of $57.73 million, a P/E ratio of -0.85 and a beta of 2.74. The stock’s 50 day moving average price is $2.23 and its 200-day moving average price is $2.59.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.